Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

PHARMACOLOGICAL CHARACTERIZATION OF APROCITENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, ALONE AND IN COMBINATION WITH BLOCKERS OF THE RENIN ANGIOTENSIN SYSTEM, IN TWO MODELS OF EXPERIMENTAL HYPERTENSION.

Trensz F, Bortolamiol C, Kramberg M, Wanner D, Hadana H, Rey M, Strasser DS, Delahaye S, Hess P, Vezzali E, Mentzel U, Menard J, Clozel M, Iglarz M.

J Pharmacol Exp Ther. 2019 Jan 8. pii: jpet.118.253864. doi: 10.1124/jpet.118.253864. [Epub ahead of print]

2.

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.

Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, Studer R, Vezzali E, Freti D, Hadana H, Schläpfer M, Cattaneo C, Bortolamiol C, Weber E, Whitby BR, Delahaye S, Wanner D, Steiner P, Nayler O, Hess P, Clozel M.

J Cardiovasc Pharmacol. 2015 Nov;66(5):457-67. doi: 10.1097/FJC.0000000000000296.

3.

Novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram positive activity and improved safety profile.

Surivet JP, Zumbrunn C, Rueedi G, Bur D, Bruyère T, Locher H, Ritz D, Seiler P, Kohl C, Ertel EA, Hess P, Gauvin JC, Mirre A, Kaegi V, Dos Santos M, Kraemer S, Gaertner M, Delers J, Enderlin-Paput M, Weiss M, Sube R, Hadana H, Keck W, Hubschwerlen C.

J Med Chem. 2015 Jan 22;58(2):927-42. doi: 10.1021/jm501590q. Epub 2014 Dec 23.

PMID:
25494934

Supplemental Content

Loading ...
Support Center